GlaxoSmithKline says five late-stage trials meet main goal
(Reuters) - GlaxoSmithKline Plc said results from five late-stage trials of two experimental quadrivalent influenza vaccines (QIV) met the main goal of protecting against mild as well as moderate-severe cases of influenza.
GSK said its experimental vaccines contain two influenza A strains and two influenza B strains to potentially help broaden protection against seasonal influenza, compared to approved trivalent vaccines that contain two A influenza strains and one B influenza strain.
(Reporting by Monika Shinghal in Bangalore)
- Tweet this
- Share this
- Digg this
- Ukraine says EU to be guarantor in any Russia gas deal
- Rebound in FTSE halted by drop in BT and commodity stocks
- Maine nurse fights Ebola quarantine, says will not be bullied |
- Shell outpaces peers with profit growth, keeps spending
- Barclays sets aside 500 million pounds for FX fines as profits rise |